Literature DB >> 3494507

Normal and malignant human urothelium: in vitro effects of epidermal growth factor.

E M Messing, C A Reznikoff.   

Abstract

Cultures of human normal urothelial (HU) cells and transitional cell carcinoma (TCC) cell lines were tested for their ability to specifically bind and respond to epidermal growth factor (EGF). The criteria of response investigated were stimulation of growth and induction of ornithine decarboxylase (ODC) activity. All four human TCC cell lines tested were stimulated to grow by EGF (1-100 ng/ml) in a dose related fashion while only one of four HU cell cultures was similarly stimulated, and growth stimulation of this cell line occurred only at early passage. TCC and HU cells bound EGF to similar degrees with Kds of 0.86 nM for TCC and 2.54 nM for HU (P greater than 0.05) and 91637 +/- 9816 (SD) (high affinity) receptors/cell for TCC and 124275 +/- 16841 for HU (P greater than 0.10). Baseline ODC activity was statistically similar in the two TCC and the three HU cell cultures tested. However, EGF induced dose related ODC activity only in the TCC cell lines and not in any of the HU cell cultures. Thus, while both malignant and normal urothelium bind EGF equally well in vitro, only TCC responds to EGF in two parameters relevant to neoplasia: growth and induction of ODC activity.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3494507

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  12 in total

Review 1.  Chemoprevention of bladder cancer.

Authors:  Dragan J Golijanin; David Kakiashvili; Ralph R Madeb; Edward M Messing; Seth P Lerner
Journal:  World J Urol       Date:  2006-11       Impact factor: 4.226

2.  Enhanced gene expression of transforming growth factor-alpha and c-met in rat urinary bladder cancer.

Authors:  M Inui; N Nishi; A Yasumoto; I Takenaka; H Miyanaka; K Matsumoto; T Nakamura; F Wada
Journal:  Urol Res       Date:  1996

3.  Heparin-binding EGF-like growth factor is an autocrine growth factor for human urothelial cells and is synthesized by epithelial and smooth muscle cells in the human bladder.

Authors:  M R Freeman; J J Yoo; G Raab; S Soker; R M Adam; F X Schneck; A A Renshaw; M Klagsbrun; A Atala
Journal:  J Clin Invest       Date:  1997-03-01       Impact factor: 14.808

4.  Relationship of epidermal growth factor receptor detectability with the A, B, H blood group antigens. Emphasis on normal and neoplastic urothelium.

Authors:  C Limas
Journal:  Am J Pathol       Date:  1991-07       Impact factor: 4.307

5.  An assessment of immunoreactive epidermal growth factor in urine of patients with urological diseases.

Authors:  N H Chow; T S Tzai; P E Cheng; C J Chang; J S Lin; M J Tang
Journal:  Urol Res       Date:  1994

6.  Isolation and characterization of a novel bladder cancer cell line: inhibition by epidermal growth factor.

Authors:  H Pratsinis; A Saetta; S Gagos; P Davaris
Journal:  In Vitro Cell Dev Biol Anim       Date:  1998-10       Impact factor: 2.416

7.  Characterization of insulin-like growth factor I binding sites in human bladder cancer cell lines.

Authors:  M Iwamura; M Ishibe; P M Sluss; A T Cockett
Journal:  Urol Res       Date:  1993-01

8.  Diphtheria toxin-epidermal growth factor fusion protein DAB389EGF for the treatment of bladder cancer.

Authors:  Xiaoping Yang; Elizabeth Kessler; Lih-Jen Su; Andrew Thorburn; Arthur E Frankel; Yuan Li; Francisco G La Rosa; Jingping Shen; Chuan-Yuan Li; Marileila Varella-Garcia; L Michael Glodé; Thomas W Flaig
Journal:  Clin Cancer Res       Date:  2012-11-21       Impact factor: 12.531

Review 9.  Intravesical suramin: a novel agent for the treatment of superficial transitional-cell carcinoma of the bladder.

Authors:  M M Walther; W D Figg; W M Linehan
Journal:  World J Urol       Date:  1996       Impact factor: 4.226

10.  Near-diploid transitional cell carcinoma: a preliminary report.

Authors:  N H Chow; T S Tzai; S N Lin; W C Su; H L Cheng
Journal:  Int Urol Nephrol       Date:  1994       Impact factor: 2.370

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.